BioCentury
ARTICLE | Clinical News

Erytech soars on pancreatic cancer readout

March 28, 2017 12:50 AM UTC

Erytech Pharma S.A. (Euronext:ERYP) rose €10.70 (75%) to €25 on Monday after it said Graspa eryaspase met the co-primary endpoints in a French Phase IIb study to treat metastatic pancreatic cancer in a second-line setting. Compared to standard of care alone, the therapy plus SOC gemcitabine or FOLFOX led to improvements in both progression-free survival and overall survival among patients with low asparagine synthetase (ASNS), with hazard ratios of 0.73 for PFS and 0.62 for OS below the study's prespecified threshold of 0.85.

Erytech said Graspa also significantly improved both PFS and OS in the study's entire 140-patient population, and was generally well tolerated. The company expects complete data to be presented at an upcoming medical conference...